FBIONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as FBIOP
Fortress Biotech, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.87+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $59.45M
- P/E (TTM)
- –
- Dividend yield
- –
Fortress Biotech, Inc. revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Journey | $68.18M | $64.68M | $61.86M | $59.40M | $56.40M | $56.24M | $56.13M | – | – | – | – | – | 99.6% | +20.9% |
| Avenue | – | – | $1.40M | – | – | – | – | – | – | – | – | – | – | – |
| Checkpoint Merger | – | – | – | – | – | – | $41.00K | – | – | – | – | – | – | – |
| Pharmaceutical and Biotechnology Product Development | – | – | – | – | – | – | – | – | – | – | $5.33M | $1.08M | – | – |
| Dermatology Products Sales | – | – | – | – | – | – | – | $57.77M | $77.68M | $80.00M | $79.18M | $79.89M | – | – |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avenue | -$2.90M | -$1.89M | -$3.08M | -$3.93M | -$6.36M | -$9.48M | -$11.28M | – | – | – | – | – | -54.4% |
| Journey | -$3.01M | -$6.40M | -$8.17M | -$5.56M | -$6.92M | -$6.91M | -$13.68M | – | – | – | – | – | -56.5% |
| Mustang | -$3.52M | -$3.24M | -$2.43M | -$2.78M | -$3.61M | -$11.27M | -$16.25M | – | – | – | – | – | -2.5% |
| Fortress | -$19.92M | -$17.39M | -$18.50M | -$10.31M | -$11.24M | -$12.00M | -$13.00M | – | – | – | – | – | +77.2% |
| Checkpoint Merger | – | – | -$38.04M | -$66.87M | -$76.59M | -$56.38M | -$56.17M | – | – | – | – | – | – |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emrosi | $24.21M | $18.93M | $14.75M | – | – | – | – | – | – | – | – | – | 35.4% | – |
| Qbrexza | $23.05M | $24.88M | $25.01M | $25.15M | $25.37M | $25.26M | $25.11M | $26.81M | $25.09M | $26.33M | $25.41M | $25.00M | 33.7% | -9.2% |
| Accutane | $12.51M | $12.54M | $12.88M | $13.69M | $14.92M | $17.24M | $19.41M | $20.59M | $21.48M | $21.34M | $20.17M | $19.25M | 18.3% | -16.2% |
| Other / legacy product revenue | $1.79M | $2.29M | $2.74M | $3.28M | $3.53M | $3.52M | $3.96M | $3.98M | $4.54M | $5.17M | $5.92M | – | 2.6% | -49.4% |
| Targadox | – | – | – | – | – | – | – | – | – | – | $3.20M | $3.80M | – | – |
| Ximino | – | – | – | – | – | – | – | – | – | – | – | $1.75M | – | – |
| Exelderm | – | – | – | – | – | – | – | – | – | – | $2.40M | $2.26M | – | – |
| Zilxi | – | – | – | – | $1.68M | $1.80M | $1.64M | $1.60M | $1.72M | $1.92M | $1.96M | $1.99M | – | – |
| Amzeeq | – | – | – | – | $5.03M | $5.35M | $5.01M | $4.80M | $5.59M | $5.76M | $6.20M | $6.25M | – | – |
| Collaboration revenue | – | – | – | – | – | – | – | – | – | – | $5.23M | – | – | – |
| Royalty revenue | – | – | $0 | – | – | – | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Fortress Biotech's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.